Genmab — Oktober 2020
-
God morgen.
-
God morgen
-
it looks like Teclistamab got orphan designation in the EU
https://ec.europa.eu/transparency/regdoc/?fuseaction=list&coteId=3&year=2020&number=7303&version=ALL&language=en (after getting the positive opinion in september https://www.ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-september-2020_en.pdf ) -
-
04.11 regnskab, 09.11 SITC starter, 13.11 CMD
-
Tjah der er Q3 4/11. Det giver nok ikke meget. Ellers i uge 46.
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/87741_target_2580_gmab.JPG handler selv efter kurs 2580 nås inden 1 Januar 2021 og benytter den røde linie som en slags stop loss (indikeret med 5 blå pile )
-
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab https://www.mdpi.com/2076-3425/10/10/758/htm
-
Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer https://www.targetedonc.com/view/updated-findings-show-continued-benefit-of-parp-in-ovarian-cancer-new-agent-on-the-scene-in-cervical-cancer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind